365 related articles for article (PubMed ID: 10513992)
1. Possible Contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells.
Banner KH; Hoult JR; Taylor MN; Landells LJ; Page CP
Biochem Pharmacol; 1999 Nov; 58(9):1487-95. PubMed ID: 10513992
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
Banner KH; Roberts NM; Page CP
Br J Pharmacol; 1995 Dec; 116(8):3169-74. PubMed ID: 8719792
[TBL] [Abstract][Full Text] [Related]
3. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.
Tenor H; Hatzelmann A; Church MK; Schudt C; Shute JK
Br J Pharmacol; 1996 Aug; 118(7):1727-35. PubMed ID: 8842438
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
5. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
6. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors.
Dent G; White SR; Tenor H; Bodtke K; Schudt C; Leff AR; Magnussen H; Rabe KF
Pulm Pharmacol Ther; 1998 Feb; 11(1):47-56. PubMed ID: 9802963
[TBL] [Abstract][Full Text] [Related]
7. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
8. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.
Landells LJ; Spina D; Souness JE; O'Connor BJ; Page CP
Pulm Pharmacol Ther; 2000; 13(5):231-9. PubMed ID: 11003567
[TBL] [Abstract][Full Text] [Related]
9. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF
Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438
[TBL] [Abstract][Full Text] [Related]
10. Evidence to suggest that the phosphodiesterase 4 isoenzyme is present and involved in the proliferation of umbilical cord blood mononuclear cells.
Banner KH; Dimitriou G; Kinali M; Page CP; Greenough A
Clin Exp Allergy; 2000 May; 30(5):706-12. PubMed ID: 10792363
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
Torphy TJ; Zhou HL; Cieslinski LB
J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
[TBL] [Abstract][Full Text] [Related]
15. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.
Landells LJ; Szilagy CM; Jones NA; Banner KH; Allen JM; Doherty A; O'Connor BJ; Spina D; Page CP
Br J Pharmacol; 2001 Jul; 133(5):722-9. PubMed ID: 11429397
[TBL] [Abstract][Full Text] [Related]
16. gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition.
Ostlere LS; Mallett RB; Kaminski A; Kaminski ER; Pereira RS; Holden CA
Br J Dermatol; 1995 Jul; 133(1):1-5. PubMed ID: 7669618
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis.
Osinski MT; Schrör K
Biochem Pharmacol; 2000 Aug; 60(3):381-7. PubMed ID: 10856433
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
Matousovic K; Tsuboi Y; Walker H; Grande JP; Dousa TP
J Lab Clin Med; 1997 Nov; 130(5):487-95. PubMed ID: 9390636
[TBL] [Abstract][Full Text] [Related]
19. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
Kim DH; Lerner A
Blood; 1998 Oct; 92(7):2484-94. PubMed ID: 9746789
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
